Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phosphate binders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Phosphate binders. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-003949-41 Sponsor Protocol Number: 36810 Start Date*: 2014-11-06
    Sponsor Name:VU medical Center
    Full Title: Role of different phosphate binders on absorption of vitamin K, metabolism of matrix γ-carboxy-glutamaat (Gla) proteïne (MGP).
    Medical condition: Vascular calcification, phosphate binders and patients on hemodialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004340-35 Sponsor Protocol Number: CAMG-14-I Start Date*: 2015-03-03
    Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Full Title: Randomized controlled trial of two different combinations of Calcium-containing Phosphate binders (Ca-PiB) plus non-Calcium-non-Aluminum containing Phosphate binders (no-Ca-Al-PiB): a pharma-econom...
    Medical condition: Hyperphosphatemia associated with Chronic Kidney Disease (CKD) in patients undergoing hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003698-24 Sponsor Protocol Number: 71254 Start Date*: 2021-09-20
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
    Medical condition: Chronic kidney disease, End-stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000488-95 Sponsor Protocol Number: 6520-9961-04 Start Date*: 2013-08-28
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG
    Full Title: Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with hyperphosphatemia
    Medical condition: Dialysis-dependent patients with hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003565-40 Sponsor Protocol Number: PA-CL-03 Start Date*: 2007-12-18
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease ...
    Medical condition: patients with chronic kidney disease undergoing hemodialysis hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004748-36 Sponsor Protocol Number: PA-CL-03A Start Date*: 2008-10-30
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label, randomized, active controlled multi center phase II dose finding study to evaluate the ability of PA21 to lower serum phosphate levels and the tolerability in patients with chronic k...
    Medical condition: Hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002582-35 Sponsor Protocol Number: MCI-196-E16 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003233-41 Sponsor Protocol Number: SVCARB00105 Start Date*: 2005-10-25
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009122 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004319-33 Sponsor Protocol Number: D5613C00001 Start Date*: 2014-04-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in E...
    Medical condition: Hyperphosphatemia in patients with end-stage renal disease on hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006320-20 Sponsor Protocol Number: CT.SVL.PD.10.001 Start Date*: 2012-05-17
    Sponsor Name:Synthon BV
    Full Title: A multicenter, randomized, double-blind, multiple dose, crossover study to evaluate the safety and equivalence of serum phosphate control of a new sevelamer carbonate tablet formulation in compari...
    Medical condition: Evaluation of the safety and equivalence of serum phosphate control of a sevelamer carbonate tablet formulation in comparison with Renvela® in chronic kidney disease patients on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-003885-16 Sponsor Protocol Number: SVCARB00606 Start Date*: 2008-08-19
    Sponsor Name:Genzyme Europe BV
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patien...
    Medical condition: Treatment of hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005416-26 Sponsor Protocol Number: ANSWER Start Date*: 2014-06-06
    Sponsor Name:Mario Negri Institute
    Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein...
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000222-35 Sponsor Protocol Number: 2017-000222-35 Start Date*: 2017-07-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial
    Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022011-19 Sponsor Protocol Number: PA-CL-05A Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomised Co...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.0 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002583-27 Sponsor Protocol Number: MCI-196-E15 Start Date*: 2013-07-11
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001787-23 Sponsor Protocol Number: CSBR759A2201 Start Date*: 2008-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels i...
    Medical condition: Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) GB (Completed) FI (Completed) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002174-32 Sponsor Protocol Number: REN00304 Start Date*: 2005-01-13
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, randomized, parallel design study to investigate the efficacy and safety of sevelamer hydrochloride (Renagel®) compared with calcium acetate in peritoneal dialysis patients (REN00304)
    Medical condition: Peritoneal dialysis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10034660 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002581-12 Sponsor Protocol Number: MCI-196-E14 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000192-33 Sponsor Protocol Number: 20120360 Start Date*: 2013-07-12
    Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of A...
    Medical condition: Chronic Kidney Disease Secondary Hyperparathyroidism (SHPT)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10064848 Chronic kidney disease LLT
    17.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed) CZ (Completed) LV (Completed) SE (Completed) AT (Completed) BE (Completed) ES (Completed) EE (Completed) DE (Completed) GR (Completed) LT (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003324-11 Sponsor Protocol Number: MCI-196-E09 Start Date*: 2007-03-28
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 19:08:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA